Abstract
Papillary thyroid carcinoma (PTC) accounts for over 90% of all thyroid cancers in Japan. The majority of patients with PTC are categorized into a low-risk group according to the recent risk-group classification schemes, and they have excellent outcomes. Several management guidelines for thyroid cancers have been published in Western countries. However, the optimal therapeutic options for PTC remain controversial and high-level clinical evidence to resolve the issues is lacking. Moreover, socioeconomic differences in medical care exist; therefore, conventional policies for the treatment of PTC have been different between Japan and other countries. This report reviews the controversy in the treatment of PTC regarding the initial surgery, postoperative adjuvant therapies, and methods of surveillance. This review focuses on the unique policy in Japan preferring to treat patients with low-risk PTC by a lessthan-total thyroidectomy without adjuvant therapies rather than a total thyroidectomy with radioactive iodine, in an attempt to maintain patients’ quality of life. In addition, the institutional efforts to improve the level of evidence for the management of PTC are introduced, such as a randomized controlled trial for the effect of thyrotropin suppression therapy, a prospective study for selective lymph node dissection based on preoperative ultrasonography, and a prospective nonsurgical observation trial for asymptomatic papillary microcarcinoma.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Davies L, Gilbert Welch H. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295:2164–2167.
Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989;95:2S–4S.
Heinrich S, Schäfer M, Rousson V, Clavien PA. Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg 2006;243:154–168.
Udelsman R, Lakatos E, Ladenson P. Optimal surgery for papillary thyroid carcinoma. World J Surg 1996;20:88–93.
Cady B, Rossi R. An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery 1988;104:947–953.
Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088–1095.
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050–1058.
Byar DP, Green SB, Dor P, Williams ED, Colon J, van Gilse HA, et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative group. Eur J Cancer 1979;15:1033–1041.
Mazzaferri EL, Jhiang S. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418–428.
Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol 1996;3:534–538.
Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998;83:1012–1021.
UICC TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss; 2002. p. 52–56.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Thyroid carcinoma. Version 1. 2008. http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf. Accessed 15 May 2009.
Noguchi S, Murakami N, Kawamoto H. Classification of papillary cancer of the thyroid based on prognosis. World J Surg 1994;18:552–558.
Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 2004;135:139–148.
Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O’sullivan B. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 1997;79:2414–2423.
Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 2007;245:366–378.
Loh KH, Greenspan FS, Gee L, Miller TR, Yeo PPB. Pathological Tumor-Node Metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82:3553–3562.
Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 2006;65:364–368.
Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, et al. BRAF (V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15\year median follow-up study. J Clin Endocrinol Metab 2008;93:3493–3499.
Cobin RH, Gharib H, Bergman DA, Clark OH, Cooper DS, Daniels GH, et al. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001;7:202–220.
British Thyroid Association, Royal College of Physicians. Guidelines for the management of thyroid cancer. 2nd ed. 2007. http://www.british-thyroid-association.org/news/Docs/Thyroid_cancer_ guidelines_2007.pdf. Accessed 15 May 2009.
The American Thyroid Association Guideline Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109–142.
Shigematsu N, Takami H, Ito N, Kubo A. Nationwide survey on the treatment policy for well-differentiated thyroid cancer: results of a questionnaire distributed at the 37th meeting of the Japanese Society of Thyroid Surgery. Endocr J 2005;52:479–491.
Cady B. Our AMES is true: how an old concept still hits the mark, or risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997;174:462–468.
Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope 2004;114:393–402.
Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981;70:511–518.
Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958–964.
Shah JP, Loree TR, Dharker D, Strong EW. Lobectomy versus total thyroidectomy for differentiated thyroid carcinoma of the thyroid: a matched-pair analysis. Am J Surg 1993;166:331–335.
Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246:375–384.
Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668–3676.
Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005;90:5047–5057.
Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. Author’s response: a consensus report of the role of serum thyroglobulin as a monitoring method for lowrisk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:4508–4510.
Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131-I whole body scan: comparison of patients treated with high 131-I activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092–4097.
Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine 1977;56:171–196.
Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81:4318–4323.
Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8:737–744.
Jonklaas J, Sarlis NJ, Litofsly D, Ain KB, Bigos T, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229–1242.
Cady B. Staging in thyroid carcinoma. Cancer 1998;83:844–847.
Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery. 1995;118:1131–1138.
Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998;82:375–388.
Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Ultrasonographically and anatomopathologically detectable node metastasis in the lateral compartment as indicators of worse relapse-free survival in patients with papillary carcinoma. World J Surg 2005;29:917–920.
Bae JS, Park WC, Song BJ, Jung SS, Kim JS. Endoscopic thyroidectomy and sentinel lymph node biopsy via an anterior chest approach for papillary thyroid cancer. Surgery Today 2009;39:178–181.
Cady B. Regional lymph node metastases, a singular manifestation of the process of clinical metastases in cancer: contemporary animal research and clinical reports suggest unifying concepts. Ann Surg Oncol 2007;14:1790–1800.
Medical Professionalism Project. Medical Professionalism in the new millennium: a physician’s charter. Lancet 2002;359:520–522.
McGriff NJ, Csako G, Gourgiotis L, Guthrie LC, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002;34:554–564.
Simon D, Goretzki PE, Witte J, Röher HD. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. World J Surg 1996;20:860–866.
Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002;26:22–28.
Marchesi M, Biffoni M, Biancari F, Berni A, Campana FP. Predictors of outcome for patients with differentiated and aggressive thyroid carcinoma. Eur J Surg Suppl 2003;588:46–50.
Noguchi S, Murakami N. Yamashita H, Toda M, Kawamoto H. Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg 1998;133:276–280.
Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, et al. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg 2007;31:2085–2091.
Sugitani I, Fujimoto Y, Yamada K, Yamamoto N. Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography. World J Surg 2008;32:2494–2502.
Takahashi S. Clinicopathological studies of latent carcinoma of the thyroid (in Japanese). Nippon Naibunpi Gakkai Zasshi (Folia Endocrinol Japon) 1969;45:65–79.
Sampson RJ, Key CR, Buncher CR, Oka H, Iijima S. Papillary carcinoma of the thyroid gland: sizes of 525 tumors found at autopsy in Hiroshima and Nagasaki. Cancer 1970;25:1391–1393.
Sampson RJ, Woolner LB, Bahn RC, Kurland LT. Occult thyroid carcinoma in Olmsted country, Minnesota: prevalence at autopsy compared with that in Hiroshima and Nagasaki, Japan. Cancer 1974;34:2072–2076.
Fukunaga FH, Yatani R. Geographic pathology of occult thyroid carcinomas. Cancer 1975;36:1095–1099.
Bondeson L, Ljungberg O. Occult thyroid carcinoma at autopsy in Malmö, Sweden. Cancer 1981;47:319–323.
Nasir A, Chaudhry AZ, Gillespie J, Kaiser HE. Papillary microcarcinoma of the thyroid: a clinico-pathologic and prognostic review. In Vivo 2000;14:367–376.
Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary microcarcinoma. World J Surg 2008;32:747–753.
Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008;144:980–988.
Rosai J, LiVolsi VA, Sobrinho-Simoes M, Williams ED. Renaming papillary microcarcinoma of the thyroid gland: the Porto proposal. Int J Surg Pathol 2003;11:249–251.
AACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006;12:63–102.
Sugitani I, Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J 1999;46:209–216.
Sugitani I, Fujimoto Y, Yamada K. Treatment strategy for patients with papillary microcarcinoma (in Japanese with English abstract). Nippon Rinsho (Jpn J Clin Med) 2007;65:2045–2048.
Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003;13:381–387.
Sugitani I, Yanagisawa A, Shimizu A, Kato M, Fujimoto Y. Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy. World J Surg 1998;22:731–737.
Fujimoto Y, Sugitani I. Postoperative prognosis of intrathyroidal papillary thyroid carcinoma: long-term (35–45 year) follow-up study. Endocr J 1998;45:475–484.
Tuttle RM. Risk-adopted management of thyroid cancer. Endocr Pract 2008;14:764–774.
Cady B. Presidential address: beyond risk groups- a new look at differentiated thyroid cancer. Surgery 1998;124:947–957.
Hoftijzer HC, Heemstra KA, Corssmit EPM, van der Klaauw AA, Romijn JA, Smit JWA. Quality of life in cured patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008;93:200–203.
Sugitani I, Fujimoto Y, Yamamoto N. Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery 2008;143:35–42.
Bilimoria KY, Zanocco K, Sturgeon C. Impact of surgical treatment on outcomes for papillary thyroid cancer. Adv Surg 2008;42:1–12.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sugitani, I., Fujimoto, Y. Management of low-risk papillary thyroid carcinoma: Unique conventional policy in Japan and our efforts to improve the level of evidence. Surg Today 40, 199–215 (2010). https://doi.org/10.1007/s00595-009-4034-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-009-4034-5